智通财经APP讯，乐普医疗(300003.SZ)公告，公司控股子公司上海民为生物技术有限公司(简称“民为生物”)收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》，由民为生物申报的MWN109注射液、MWN105注射液临床试验申请获得批准。
根据公告所示，MWN105注射液适应症为：超重或肥胖适应症、2型糖尿病;MWN109注射液适应症为：2型糖尿病、超重或肥胖适应症。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.